Payment overview · 2025
General Payments
$398.36
16 reported records · 6 companies
Healthcare provider profile · identity verified
Desiree Townsend Davis, AGPCNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · VANCEBORO, NC · NPI 1215493572
Verified facts
What the public records show
CMS Open Payments records show Desiree Townsend Davis, AGPCNP received $398.36 in general payments during 2025 across 16 reported records.
Novo Nordisk Inc accounted for 36.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $144.16 | 36.2% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $78.83 | 19.8% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $57.24 | 14.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.22 | 14.4% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.15 | 10.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.76 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $398.36 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $144.16 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $57.24 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.22 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $40.15 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $31.09 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.01 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.42 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 126 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 41 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
126 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 300 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 234 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 43 |
| Omeprazole | Omeprazole | 161 | 49 |
| Lisinopril | Lisinopril | 156 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 152 | 38 |
| Losartan Potassium | Losartan Potassium | 149 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 42 |
| Farxiga | Dapagliflozin Propanediol | 126 | 26 |
| Gabapentin | Gabapentin | 113 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 112 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 28 |
| Montelukast Sodium | Montelukast Sodium | 94 | 26 |
| Potassium Chloride | Potassium Chloride | 90 | 25 |
| Furosemide | Furosemide | 89 | 28 |
| Metformin Hcl | Metformin Hcl | 85 | 27 |
| Metformin Hcl Er | Metformin Hcl | 78 | 32 |
| Tramadol Hcl | Tramadol Hcl | 78 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 21 |
| Carvedilol | Carvedilol | 72 | 23 |
| Nifedipine Er | Nifedipine | 71 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 18 |
| Trazodone Hcl | Trazodone Hcl | 66 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 20 |
| Celecoxib | Celecoxib | 61 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | suppressed |
| Eliquis | Apixaban | 58 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 16 |
| Famotidine | Famotidine | 57 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 14 |
| Meloxicam | Meloxicam | 44 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 43 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 14 |
| Allopurinol | Allopurinol | 42 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | suppressed |
| Jardiance | Empagliflozin | 41 | 17 |
| Ozempic | Semaglutide | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 14 |
| Cephalexin | Cephalexin | 34 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 14 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Naproxen | Naproxen | 33 | 13 |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Prednisone | Prednisone | 31 | 25 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 25 | 13 |
| Linzess | Linaclotide | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Mitigare | Colchicine | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $398.36 · 16 records | Novo Nordisk Inc | BREZTRI, FARXIGA, JARDIANCE, Kerendia, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error